Determination of SNX-2112, a Selective Hsp90 Inhibitor, in Plasma Samples by High-Performance Liquid Chromatography and Its Application to Pharmacokinetics in Rats
Qian-Qian Zhai,Guo-Qin Gong,Yong Luo,Qing-Duan Wang,Min Xia,Guo-Wen Xing,Yi-Cheng Li,Jin-Hua Jiang,Zhong Liu,Qiu-Ying Liu,Yi-Fei Wang
DOI: https://doi.org/10.1016/j.jpba.2010.06.031
IF: 3.571
2010-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:A sensitive and specific reversed-phase high-performance liquid chromatography method with ultraviolet detection has been developed and validated for the identification and quantification of SNX-2112 in rat plasma. Following sample preparation using liquid–liquid extraction, the analytes were separated by the mobile phase acetonitrile–water (40:60, v/v) with an Agilent RP-HPLC column (ZORBAX SB-C18, 5μm, 4.6mm×250mm) at a flow rate of 1ml/min, column temperature of 30°C and detection wavelength of 251nm. The retention time of SNX-2112 was 11.2min. A good linear relationship was obtained in the concentration range studied (0.07–21μg/ml, R2>0.9982), and the LLOD and LLOQ for SNX-2112 were 0.02 and 0.07μg/ml, respectively. The mean absolute recovery of SNX-2112 in plasma ranged from 88.58 to 99.61% at the studied concentrations. The intra- and inter-batch relative standard deviations were 1.7–3.5 and 1.9–4.4%, respectively. This method was successfully applied to pharmacokinetic studies in rats after intravenous administration of SNX-2112.